Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial | Semantic Scholar
Effects of COX Inhibition on Blood Pressure and Kidney Function in ACE Inhibitor-Treated Blacks and Hispanics | Hypertension
Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016
Selective COX-2 inhibitors: Are they safer NSAIDs?
Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library
Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM
Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study | Annals of the Rheumatic Diseases
Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen - ScienceDirect
Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison | Semantic Scholar
Drug Information from Guideline Central
Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison - The Lancet
Celecoxib: the “need to know” for safe prescribing - bpacnz
Celebrex vs. Mobic: What's the Difference?
Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial | Semantic Scholar
Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: A retrospective cohort study | PLOS ONE
Cancers | Free Full-Text | Development and Challenges of Diclofenac-Based Novel Therapeutics: Targeting Cancer and Complex Diseases